menu
    • menu
    [{"orgOrder":0,"company":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","sponsor":"Ashvattha Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"OP-101","moa":"Glutathione synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical"},{"orgOrder":0,"company":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical"},{"orgOrder":0,"company":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.089999999999999997,"dosageForm":"Topical Cream","sponsorNew":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical"},{"orgOrder":0,"company":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","sponsor":"Immunogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Mirvetuximab Soravtansine","moa":"Tubulin | Folate receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","amount2":0.31,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.31,"dosageForm":"Undisclosed","sponsorNew":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Hangzhou Huadong Medicine Group Kangrun Pharmaceutical

    Menu

    Hangzhou Huadong Medicine Group Kangrun Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hangzhou Huadong Medicine Group Kangrun Pharmaceutical

                            China arrow
                            iPHEX India
                            Not Confirmed

                            Hangzhou Huadong Medicine Group Kangrun Pharmaceutical

                            China arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roflumilast

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Recipient : Arcutis Biotherapeutics

                            Deal Size : $94.2 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greate...

                            Details : Under the collaboration, Huadong will receive license for both the cream and foam formulations of topical Zoryve (roflumilast), a next generation PDE4 inhibitor, for multiple dermatological conditions including plaque psoriasis, seborrheic dermatitis, an...

                            Product Name : Zoryve

                            Product Type : Other Small Molecule

                            Upfront Cash : $30.0 million

                            October 08, 2023

                            Lead Product(s) : Roflumilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Recipient : Arcutis Biotherapeutics

                            Deal Size : $94.2 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hangzhou Huadong Medicine Group Kangrun Pharmaceutical

                            China arrow
                            iPHEX India
                            Not Confirmed

                            Hangzhou Huadong Medicine Group Kangrun Pharmaceutical

                            China arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OP-101

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Ashvattha Therapeutics

                            Deal Size : $45.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ashvattha Therapeutics Announces $69 Million in Series B Financing and up to $45M Exclusive License Agreement ...

                            Details : Under the terms of the exclusive licensing agreement, Huadong will advance research and development costs for Ashvattha’s hydroxyl dendrimer clinical candidates, OP-101, D-4517.2 and OP-801, and for additional preclinical candidates.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 27, 2022

                            Lead Product(s) : OP-101

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Ashvattha Therapeutics

                            Deal Size : $45.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Hangzhou Huadong Medicine Group Kangrun Pharmaceutical

                            China arrow
                            iPHEX India
                            Not Confirmed

                            Hangzhou Huadong Medicine Group Kangrun Pharmaceutical

                            China arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zevorcabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : CARsgen Therapeutics

                            Deal Size : $181.3 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            CARsgen, Huadong Medicine Ink Deal To Sell CAR T-cell Product In China

                            Details : CT053 (zevorcabtagene autoleucel), is a fully human, autologous BCMA CAR T-cell product candidate for the treatment of relapsed/refractory multiple myeloma (R/R MM).

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : $29.6 million

                            January 16, 2022

                            Lead Product(s) : Zevorcabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : CARsgen Therapeutics

                            Deal Size : $181.3 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hangzhou Huadong Medicine Group Kangrun Pharmaceutical

                            China arrow
                            iPHEX India
                            Not Confirmed

                            Hangzhou Huadong Medicine Group Kangrun Pharmaceutical

                            China arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Immunogen

                            Deal Size : $305.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Sora...

                            Details : Partnership accelerates development path for Mirvetuximab in Greater China and expands Huadong Medicine’s oncology portfolio with innovative ADC.

                            Product Name : Elahere

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : $40.0 million

                            October 19, 2020

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Immunogen

                            Deal Size : $305.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth